MedTrace Logo

Study of CM518D1 in Patients With Advanced Solid Tumors

NCT07019779 · Status: RECRUITING · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 434

Last updated 2025-11-17

No results posted yet for this study

Summary

This is an interventional study to assess the safety, tolerability, efficacy, pharmacokinetics, and immunogenicity of CM518D1 in patients with advanced solid tumors.

Conditions

Interventions

BIOLOGICAL

CM518D1

CM518D1 will be administered intravenously once every 3 weeks (Q3W) in 6 predetermined dose levels.

BIOLOGICAL

CM518D1

CM518D1 will be administered intravenously once every 3 weeks (Q3W) in one or more potential recommended phase 2 dose(RP2D).

BIOLOGICAL

CM518D1

CM518D1 will be administered intravenously once every 3 weeks (Q3W) in different types of solid tumor cohorts.

Sponsors & Collaborators

  • Keymed Biosciences Co.Ltd

    lead INDUSTRY

Principal Investigators

  • Ruihua Xu · Sun Yat-sen University

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-06-27
Primary Completion
2028-12-31
Completion
2029-12-31

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07019779 on ClinicalTrials.gov